Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup-Reference-Cited by-同舟云学术

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

Published:2012-03 Issue:5 Volume:48 Page:703-712
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

McTiernan Anne,Jinks Rachel C.,Sydes Matthew R.,Uscinska Barbara,Hook Jane M.,van Glabbeke Martine,Bramwell Vivien,Lewis Ian J.,Taminiau Antonie H.M.,Nooij Marianne A.,Hogendoorn Pancras C.W.,Gelderblom Hans,Whelan Jeremy S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution;Bacci;Cancer,2006

2. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols;Bielack;J Clin Oncol,2002

3. Prognostic factors in osteosarcoma: a critical review;Davis;J Clin Oncol,1994

4. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup;Souhami;Lancet,1997

5. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup;Hauben;Eur J Cancer,2002

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO;European Journal of Cancer;2024-09

2. Dose-limiting mucositis: friend or foe?;Supportive Care in Cancer;2023-10

3. Molecular mechanisms of microRNA-301a during tumor progression and metastasis;Pathology - Research and Practice;2023-07

4. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment;International Journal of Nanomedicine;2022-03

5. Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma;BMJ Open;2021-12